Adial Pharmaceuticals
ADIL
14 hedge funds and large institutions have $495K invested in Adial Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
202% more capital invested
Capital invested by funds: $164K → $495K (+$331K)
56% more funds holding
Funds holding: 9 → 14 (+5)
0.68% more ownership
Funds ownership: 0.19% → 0.87% (+0.68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$349K |
| 2 |
Renaissance Technologies
New York
|
+$50.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$55 |
ADIL Hedge Fund Activity: Q4 2023 in Review
14 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2023, worth a combined $495K — up 202% from $164K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ADIL positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $349K. The largest seller was Morgan Stanley, exiting entirely with an estimated $55 sold.
- 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2023, up from 9 in Q3 2023.
- Funds reported $495K of Adial Pharmaceuticals stock for Q4 2023, up 202% quarter-over-quarter.
- 6 funds opened new Adial Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +5 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $349K added.
- The largest Adial Pharmaceuticals seller in Q4 2023 was Morgan Stanley, an estimated $55 sold.
Based on aggregated 13F filings for Q4 2023.